News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
70,741 Results
Type
Article (3272)
Company Profile (37)
Press Release (67431)
Multimedia
Podcasts (9)
Webinars (1)
Section
Business (25802)
Career Advice (92)
Deals (4147)
Drug Delivery (15)
Drug Development (10245)
Employer Resources (13)
FDA (1916)
Job Trends (1973)
News (38328)
Policy (2676)
Tag
2027 Biotech Bay Standard (2)
2027 Biotech Beach Elite (1)
2027 Biotech Beach Standard (1)
2027 Genetown Elite (1)
2027 Pharm Country Premier (1)
Academia (222)
Accelerated approval (10)
ADA (5)
Adcomms (6)
Allergies (25)
Alliances (3149)
ALS (17)
Alzheimer's disease (255)
Antibody-drug conjugate (ADC) (81)
Approvals (2062)
Artificial intelligence (55)
ASCO (52)
Autoimmune disease (53)
Automation (3)
Bankruptcy (30)
Best Places to Work (1758)
BIO (1)
Biologics (1)
BIOSECURE Act (1)
Biosimilars (22)
BioSpace Insights (5)
Biotechnology (30)
Bladder cancer (53)
Brain cancer (7)
Breast cancer (146)
Cancer (977)
Cardiovascular disease (97)
Career advice (84)
Career pathing (1)
CAR-T (20)
CDC (11)
CDMO (7)
Celiac Disease (1)
Cell therapy (91)
Cervical cancer (7)
Clinical research (9843)
Collaboration (178)
Commercialization (2)
Compensation (219)
Complete response letters (6)
COVID-19 (358)
CRISPR (10)
C-suite (70)
Cystic fibrosis (14)
Data (1475)
Denatured (1)
Depression (17)
Dermatology (20)
Diabetes (97)
Diagnostics (743)
Digital health (15)
Diversity (1)
Diversity, equity & inclusion (7)
Drug discovery (26)
Drug pricing (21)
Drug shortages (1)
Duchenne muscular dystrophy (27)
Earnings (19190)
Editorial (5)
Employer resources (14)
Events (8880)
Executive appointments (65)
FDA (2626)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (5)
Frontotemporal dementia (8)
Funding (143)
Gene editing (23)
Generative AI (7)
Gene therapy (56)
GLP-1 (181)
Government (422)
Grass and pollen (2)
Guidances (197)
Healthcare (1938)
Hematology (25)
HIV (20)
Huntington's disease (6)
IgA nephropathy (16)
Immunology and inflammation (46)
Immuno-oncology (11)
Indications (40)
Infectious disease (437)
Inflammatory bowel disease (19)
Inflation Reduction Act (2)
Influenza (40)
Intellectual property (26)
Interviews (13)
IPO (2667)
IRA (4)
Job creations (305)
Job search strategy (69)
JPM (5)
Kidney cancer (11)
Labor market (13)
Layoffs (56)
Leadership (3)
Legal (381)
Licensing (1)
Liver cancer (15)
Longevity (2)
Lung cancer (166)
Lymphoma (120)
Machine learning (6)
Management (3)
Manufacturing (106)
MASH (29)
Medical device (1626)
Medtech (1667)
Mergers & acquisitions (1630)
Metabolic disorders (247)
mRNA (30)
Multiple sclerosis (37)
NASH (3)
Neurodegenerative disease (40)
Neuropsychiatric disorders (7)
Neuroscience (425)
NextGen: Class of 2026 (506)
Non-profit (346)
Now hiring (3)
Obesity (115)
Opinion (19)
Ovarian cancer (53)
Pain (35)
Pancreatic cancer (31)
Parkinson's disease (38)
Partnered (3)
Patents (60)
Patient recruitment (103)
Peanut (10)
People (2980)
Pharmaceutical (4)
Pharmacy benefit managers (5)
Phase 1 (2335)
Phase 2 (3873)
Phase 3 (4260)
Pipeline (2257)
Policy (32)
Postmarket research (417)
Preclinical (650)
Press Release (1)
Prostate cancer (40)
Psychedelics (3)
Radiopharmaceuticals (40)
Rare diseases (134)
Real estate (416)
Recruiting (4)
Regenerative medicine (1)
Regulatory (2636)
Reports (12)
Research institute (210)
Resumes & cover letters (10)
Rett syndrome (2)
RNA editing (1)
RSV (18)
Schizophrenia (23)
Series A (26)
Series B (23)
Service/supplier (1)
Sickle cell disease (19)
Special edition (5)
Spinal muscular atrophy (25)
Sponsored (2)
Startups (312)
Stomach cancer (2)
Supply chain (10)
Tariffs (5)
The Weekly (8)
Vaccines (219)
Venture capital (11)
Weight loss (70)
Women's health (20)
Worklife (2)
Date
Today (8)
Last 7 days (52)
Last 30 days (214)
Last 365 days (4007)
2026 (2886)
2025 (3950)
2024 (4543)
2023 (4748)
2022 (5551)
2021 (5918)
2020 (5844)
2019 (4858)
2018 (3660)
2017 (3073)
2016 (2515)
2015 (3395)
2014 (2332)
2013 (1654)
2012 (1750)
2011 (2052)
2010 (1665)
Location
Africa (60)
Alabama (7)
Arizona (20)
Asia (4114)
Australia (443)
California (2609)
Canada (385)
China (177)
Colorado (80)
Connecticut (66)
Delaware (89)
Europe (8762)
Florida (230)
Georgia (64)
Hawaii (1)
Idaho (1)
Illinois (167)
India (11)
Indiana (111)
Japan (112)
Kansas (48)
Kentucky (8)
Louisiana (12)
Maine (8)
Maryland (199)
Massachusetts (1173)
Michigan (50)
Minnesota (89)
Mississippi (1)
Missouri (13)
Montana (4)
Nebraska (4)
Nevada (14)
New Hampshire (12)
New Jersey (628)
New Mexico (1)
New York (357)
North Carolina (204)
North Dakota (1)
Northern California (1739)
Ohio (40)
Oklahoma (3)
Oregon (3)
Pennsylvania (312)
Puerto Rico (4)
Rhode Island (3)
South America (90)
South Carolina (6)
Southern California (647)
Tennessee (54)
Texas (224)
United States (6959)
Utah (55)
Vermont (1)
Virginia (36)
Washington D.C. (7)
Washington State (152)
West Virginia (1)
Wisconsin (16)
70,741 Results for "65".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Regentis Biomaterials Announces Pricing of a $6.5 Million Private Placement
June 18, 2026
·
7 min read
Mergers & acquisitions
Servier frees Edgewise for cardio mission with $2.65B muscular dystrophy deal
Edgewise Therapeutics will now focus on a handful of cardiovascular programs including EDG-7500 for hypertrophic cardiomyopathy thanks to the non-dilutive capital from France’s Servier.
June 1, 2026
·
2 min read
·
Annalee Armstrong
Press Releases
AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market under NYSE American Rules
June 9, 2026
·
6 min read
Press Releases
QT Imaging Reports First Quarter 2026 Revenue of $6.5 Million
May 14, 2026
·
19 min read
Press Releases
Draig Therapeutics Closes Oversubscribed $65 Million Series B to Accelerate Development of Highly Specific AMPA and GABAA Receptor Modulators in Neuropsychiatric Disorders
July 14, 2026
·
3 min read
Press Releases
Edgewise Therapeutics Completes Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline
July 13, 2026
·
9 min read
Approvals
RevMed receives early FDA approval for ‘groundbreaking’ pancreatic cancer drug
The FDA granted the approval of Revolution Medicines’ daraxonrasib, now to be known as Rasonque, in pancreatic adenocarcinoma 6.5 months ahead of deadline.
August 26, 2026
·
2 min read
·
Annalee Armstrong
Press Releases
Carecubes Closes $6.5 Million Series A to Transform Infectious Disease Response
March 19, 2026
·
5 min read
Press Releases
Diabetes Management Supplements Market Size to Hit USD 17.7 Billion by 2035 at 8.65% CAGR
April 17, 2026
·
1 min read
Press Releases
Pharmaceutical CRO & CDMO Market Forecast from USD 254.65 Bn to USD 594.07 Bn by 2035
April 14, 2026
·
1 min read
1 of 7,075
Next
